Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | LSS | P48449 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10982191 | 1.00 | DRD2 (0.56) | DRD2LSSIDO1CYP2C9ESR2 | |
| SCHEMBL8015280 | 0.94 | DRD2 (0.51) | DRD2LSSIDO1CYP2C9ESR2 | |
| SCHEMBL7508508 | 0.94 | DRD2 (0.51) | DRD2LSSIDO1CYP2C9ESR2 | |
| SCHEMBL8029049 | 0.94 | DRD2 (0.51) | DRD2LSSIDO1CYP2C9ESR2 | |
| SCHEMBL8015276 | 0.94 | DRD2 (0.51) | DRD2LSSIDO1CYP2C9ESR2 | |
| SCHEMBL8029040 | 0.94 | DRD2 (0.51) | DRD2LSSIDO1CYP2C9ESR2 | |
| SCHEMBL8453164 | 0.90 | DRD2 (0.47) | DRD2LSSIDO1CYP2C9ESR2 | |
| SCHEMBL8453170 | 0.90 | DRD2 (0.47) | DRD2LSSIDO1CYP2C9ESR2 | |
| SCHEMBL8453175 | 0.90 | DRD2 (0.47) | DRD2LSSIDO1CYP2C9ESR2 | |
| SCHEMBL11187444 | 0.89 | ESR2 (0.52) | DRD2CYP2C9ESR2ESR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043959-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2023-02-09 | — | — | US | disclosed |
| US-20220411390-A1 | MODULATION OF BACTERIAL QUORUM SENSING WITH SYNTHETIC LIGANDS | WISCONSIN ALUMNI RES FOUND (US) | 2022-12-29 | — | — | US | disclosed |
| EP-3331965-B1 | LIQUID CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2022-01-05 | — | — | EP | disclosed |
| US-20180223187-A1 | LIQUID CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2018-08-09 | — | — | US | disclosed |
| US-20180223187-A1 | LIQUID CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2018-08-09 | — | — | US | disclosed |
| US-9796694-B2 | Modulation of bacterial quorum sensing with synthetic ligands | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2017-10-24 | — | — | US | disclosed |
| WO-2017020998-A1 | LIQUID CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2017-02-09 | — | — | WO | disclosed |
| US-9067951-B2 | Process and intermediates for the production of CCR2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| US-20140336374-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-8835440-B2 | Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for treatment of inflammation, asthma and COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-16 | — | — | US | disclosed |
| EP-2366756-A2 | Liquid Crystal Composition and Liquid Crystal Display Element | JNC Corporation (JP) | 2011-09-21 | — | — | EP | disclosed |
| US-7985755-B2 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-07-26 | — | — | US | disclosed |
| EP-2182044-A1 | LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | Chisso Corporation (JP) | 2010-05-05 | — | — | EP | disclosed |
| EP-2182043-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | Chisso Corporation (JP) | 2010-05-05 | — | — | EP | disclosed |
| EP-2116587-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | Chisso Corporation (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20090042900-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | DECODE CHEMISTRY, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008116029-A1 | MODULATION OF BACTERIAL QUORUM SENSING WITH SYNTHETIC LIGANDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-0074608-B1 | LIQUID CRYSTAL HALOGEN COMPOUNDS, PROCESS FOR THEIR PREPARATION, DIELECTRIC AND DECTROOPTICAL DISPLAY ELEMENT CONTAINING THEM | MERCK PATENT GmbH (DE) | 1985-07-03 | — | — | EP | disclosed |
| US-4490305-A | Liquid-crystalline halogen compounds, process for their preparation, dielectrics containing these, and electro-optical display element | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-12-25 | — | — | US | disclosed |
| EP-0074608-A2 | Liquid crystal halogen compounds, process for their preparation, dielectric and dectrooptical display element containing them | MERCK PATENT GmbH (DE) | 1983-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411390-A1 | MODULATION OF BACTERIAL QUORUM SENSING WITH SYNTHETIC LIGANDS | AHCYL1, EBPL, AIP | DRD2 3214/4885LSS 110/4885IDO1 533/4885 |
| US-20140336374-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS | CCR2, CCR5, CCR1 | DRD2 760/4885LSS 3232/4885IDO1 357/4885 |
| US-20230043959-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | DRD2 800/4885LSS 4400/4885IDO1 62/4885 |
| US-20090042900-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | SMN1; SMN2, MUSK, MYT1 | DRD2 3588/4885LSS 4677/4885IDO1 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.